… Statistical data shows that over 90% mortality of cancer … results in acquisition of the MDR
phenotype. Furthermore, the … the development of chemoresistance of various types of cancer. In …

… killer (NK)/T-cell NHLs expressing CD56. Chemotherapy is … Ofatumumab is a fully humanized
second-generation type I … Consequently, ibritumomab tiuxetan acquired FDA approval …

… Whole-exome sequencing of PTCL-NOS has revealed … With the use of classical and
next-generation sequencing … -NOS; 12% AITL) the pralatrexate study reported a median OS of …

… useful as the next generation of diagnostic biomarkers for the … risk assessment of CML
revealed that epigenetic alterations, … or peripheral T-cell lymphoma, and phase 1/2 trials on …

… cutaneous T cell lymphoma (CTCL), the CTCL derived cell line … have revealed that DNMT3A
mutations are not uncommon in both … Pralatrexate is a folate antagonist that inhibits the …

… This group has also developed a second generation of a specific … are prone to acquire
chromatin mutations which do not … revealed pathways associated with negative regulation of αβ …

… 5 of 6 patients who acquired resistance to ibrutinib. Additional … The diarrhea presented as
one of two types: either a self-… in patients with peripheral T-cell lymphoma; the ORR was 89%, …

… resistant to innovative treatments—including CAR-T-cell … in the case of resistance to first-
and second-generation TKI. … Table 7 shows the characteristics of genes present in ALL Ph…

… , from first-generation epigenetic therapies like histone acetyl … CTLA-4, which leads to T-cell
exhaustion. The effects of HDACi … In relation with this, the BETi BI-894999 shows profound …

… Recent advances in the field of epigenetics have revealed … for the treatment of cutaneous
T-cell lymphoma (CTCL), … Most notably, the combination of romidepsin with pralatrexate in a …